Immucell (ICCC) Cash from Investing Activities (2010 - 2025)
Immucell's (ICCC) quarterly Cash from Investing Activities came in at -$167306.0 in Q4 2025, up 14.73% on a YoY basis from -$145821.1 in Q4 2024, and up 71.74% quarter-over-quarter from -$592024.0 in Q3 2025.
Powered by 
Analysis
Immucell (ICCC) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Immucell (ICCC) has reported Cash from Investing Activities for 16 consecutive years, with -$167306.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 14.73% year-over-year to -$167306.0; the trailing twelve-month figure through Dec 2025 stood at -$1.2 million (down 163.28% YoY), and the FY2025 full-year result was -$1.2 million, down 163.28% from the prior year.
- Cash from Investing Activities rose to -$167306.0 in Q4 2025 per ICCC's latest filing, from -$592024.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $656684.0 in Q1 2021 and bottomed at -$1.5 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$456360.2 across 5 years, with a median of -$562641.5 in 2023.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 102.27% in 2023, then slumped 680.81% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$703279.0 in 2021, then sank by 111.89% to -$1.5 million in 2022, then jumped by 102.27% to $33783.0 in 2023, then plunged by 680.81% to -$196216.0 in 2024, then rose by 14.73% to -$167306.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$167306.0, -$592024.0, and -$125927.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | -25.50 Mn |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | -300.00 Mn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | -110.00 Mn |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | -16.45 Mn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -55,116.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -167,306.00 |
| Sep 30, 2025 | -592,024.00 |
| Jun 30, 2025 | -125,927.00 |
| Mar 31, 2025 | -329,050.00 |
| Dec 31, 2024 | -196,216.00 |
| Sep 30, 2024 | -88,412.00 |
| Jun 30, 2024 | -106,241.00 |
| Mar 31, 2024 | -70,356.00 |
| Dec 31, 2023 | 33,783.00 |
| Sep 30, 2023 | -533,259.00 |
| Jun 30, 2023 | -708,412.00 |
| Mar 31, 2023 | -682,151.00 |
| Dec 31, 2022 | -1.49 Mn |
| Sep 30, 2022 | -734,309.00 |
| Jun 30, 2022 | -943,290.00 |
| Mar 31, 2022 | -796,496.00 |
| Dec 31, 2021 | -703,279.00 |
| Sep 30, 2021 | -671,425.00 |
| Jun 30, 2021 | -879,339.00 |
| Mar 31, 2021 | 656,684.00 |